LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer

Francesca Lovat, Hideshi Ishii, Monica Schiappacassi, Matteo Fassan, Mattia Barbareschi, Enzo Galligioni, Pierluigi Gasparini, Gustavo Baldassarre, Carlo M. Croce, Andrea Vecchione

Research output: Contribution to journalArticlepeer-review

Abstract

The Leucine Zipper Tumor Suppressor 1 (LZTS1) is a tumor suppressor gene, located at chromosome 8p22, which is frequently altered in human cancer. In normal tissue, its ubiquitous expression regulates cell mitosis by the stabilization of microtubule networks. LZTS1-deficient mouse embryonic fibroblasts have been shown to have an accelerated mitotic progression, and a higher resistance to taxanes, microtubule-stabilizing drugs. We investigate the role of Lzts1 in paclitaxel-resistance in breast cancer cells. Downregulation of Lzts1 expression significantly decreases sensitivity to paclitaxel in vitro. We further analyzed Lzts1 expression by immunohistochemistry in 270 primary breast cancer samples and 16 normal breast specimens. Lzts1 was significantly downregulated in breast cancer samples and its deregulation was associated with a higher incidence of tumor recurrence, and to a worse overall survival. Moreover, Lzts1-negative tumors were associated with unfavorable outcome after taxanes-based therapy. Thus our data suggest that Lzts1 deregulation is involved in breast cancer and its immunohistochemical evaluation may serve as a prognostic factor for breast cancer therapy.

Original languageEnglish
Pages (from-to)970-977
Number of pages8
JournalOncotarget
Volume5
Issue number4
Publication statusPublished - 2014

Keywords

  • Breast cancer
  • Lzts1/Fez1
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer'. Together they form a unique fingerprint.

Cite this